QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Bioheart, Inc. (BHRT) Obtains Exclusive Rights To Adipose Technology 0 comments
    Feb 15, 2012 10:39 AM | about stocks: BHRT

    Yesterday, Bioheart, Inc. announced that it had acquired exclusive worldwide rights to adipose cell technology from Ageless Regenerative Institute, LLC. Adipose tissue is fat-based and has been shown to be rich in microvascular, myogenic, and angiogenic cells, which makes it the perfect candidate for use in the cardiac field.

    Bioheart is focused on the cardiovascular sector of the cell technology industry with the development and commercialization of autologous cell therapies (pending approval). The company is specifically targeting their concentration in areas such as congestive heart failure, lower limb ischemia, chronic heart ischemia, and acute myocardial infarctions, among others. The company's flagship product, MyoCell, helps to repair areas of scar tissue in patient hearts with living cells.

    According to the terms of the contract with Ageless, Bioheart will maintain an exclusive worldwide license to all of Ageless technology for use in the heart attack and heart failure markets, with upfront and milestone equity payments to Ageless.

    Bioheart has applied to the FDA to commence trials that will use LipiCell (adipose-derived stem cells). This will be accomplished with endocardial implantations, using the MyoStar™ Injection Catheter. This process will be under the guidance of the NOGA® cardiac navigation system, developed by Biosense Webster, Inc.

    Mike Tomas, president and CEO of Bioheart, said, "The Ageless adipose stem cell technology will allow us to broaden our portfolio of product candidates for cardiac patients. We have successfully treated patients in Mexico and now we are ready to expand into the US."

    Sharon McQuillan, Ageless' president and CEO, added, "We are excited about this collaboration with Bioheart, a leader in developing cell therapies for cardiovascular disease. Together with Bioheart, we can help to revolutionize cardiovascular medicine and improve the current standard of care for these patients."

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: BHRT
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.